TABLE 2.

Diagnostic role of miRNAs in AD patients.

MicroRNA	Expression pattern	Samples	ROC curve analysis			Clinical significance	References
			Sensitivity	Specificity	AUC
miR-17-5p miR-21-5p miR-126-3p	Upregulated	Plasma samples from 116 AD patients and 41 control individuals	– 55.0% 38.3%	– 70.7% 87.5%	– 0.68 0.62	AD diagnosis and assessment for development and progression of cognitive impairment in AD	Giuliani et al., 2021
miR-9-5p	Downregulated	Whole-blood samples from 36 AD patients and 38 control individuals	–	–	–	Diagnosis for late-onset AD	Souza et al., 2020
miR-29a	Upregulated	CSF samples from 18 AD patients and 20 control individuals	89.0%	70.0%	0.87	AD diagnosis	Müller et al., 2016
miR-34a miR-146a	Downregulated	Plasma samples from 10 AD patients and 10 control individuals	–   –	–   –	–   –	AD diagnosis	Kiko et al., 2014
miR-34a miR-125b miR-146a	Downregulated	CSF samples from 10 AD patients and 10 control individuals	– – –	– – –	– – –
miR-29a miR-29b	Upregulated		– –	– –	– –
miR-125b	Downregulated	Serum samples from 105 AD patients and 115 control individuals	80.8%	68.3%	0.85	AD diagnosis and assessment the degree of cognitive impairment	Tan et al., 2014
miR-126-5p	Upregulated	Serum samples from 105 AD patients and 115 control individuals	72.7%	60.5%	0.72	Early diagnosis of AD	Guo et al., 2017
miR-181c-3p	Downregulated		71.9%	73.3%	0.78
miR-146a miR-181a	Upregulated	Blood samples from 45 mild cognitive impairment patients	– –	– –	– –	Predicting the development of AD	Ansari et al., 2019

AD, Alzheimer’s disease; AUC, area under curve; ROC, receiver operating characteristic.